Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report)'s stock price reached a new 52-week low during trading on Monday . The company traded as low as $32.70 and last traded at $33.11, with a volume of 15958 shares traded. The stock had previously closed at $34.26.
Wall Street Analysts Forecast Growth
XENE has been the subject of a number of research reports. StockNews.com raised Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $67.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, Royal Bank of Canada reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $57.38.
Check Out Our Latest Report on XENE
Xenon Pharmaceuticals Stock Up 2.7 %
The stock has a market cap of $2.41 billion, a PE ratio of -11.16 and a beta of 1.26. The firm has a fifty day moving average of $37.29 and a 200 day moving average of $39.57.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.05. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.
Insider Activity at Xenon Pharmaceuticals
In related news, CEO Ian Mortimer sold 16,315 shares of the company's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,267,731. This represents a 34.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.52% of the company's stock.
Institutional Investors Weigh In On Xenon Pharmaceuticals
Large investors have recently modified their holdings of the company. Erste Asset Management GmbH acquired a new stake in Xenon Pharmaceuticals during the 3rd quarter worth $1,932,000. HighVista Strategies LLC boosted its stake in shares of Xenon Pharmaceuticals by 1.4% during the third quarter. HighVista Strategies LLC now owns 73,762 shares of the biopharmaceutical company's stock worth $2,904,000 after buying an additional 1,047 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock worth $100,506,000 after buying an additional 1,507,135 shares during the last quarter. State Street Corp increased its position in Xenon Pharmaceuticals by 13.2% in the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock valued at $11,004,000 after acquiring an additional 32,701 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Xenon Pharmaceuticals by 31.0% during the 3rd quarter. Two Sigma Advisers LP now owns 273,700 shares of the biopharmaceutical company's stock worth $10,776,000 after acquiring an additional 64,800 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
